Mme Docteur NICOLE GARNIER
✨ Profil synthétique
IA · 30/04/2026Mme Docteur NICOLE GARNIER est une rhumatologue libérale à Plaisance-du-Touch, titulaire d'un DIU en Médecine manuelle. Ses recherches académiques, bien que peu nombreuses (h-index de 1), couvrent des domaines variés, notamment la rhumatologie et les études historiques. Elle a publié sur des sujets tels que le lupus et la pédiatrie.
Expertises présumées
- Médecine manuelle
- Rhumatologie pédiatrique
- Lupus
- Rhumatoides
- Pédiatrie
Synthèse automatique à partir des sources publiques (HAL, OpenAlex, theses.fr, ClinicalTrials.gov, FAI²R, ANS). Pas une évaluation clinique. Le médecin peut corriger via son compte.
Diplômes
🎓 DES & spécialité ordinale
- DES Rhumatologie
- Rhumatologie (SM)
🏅 DU / DIU
- DIU Médecine manuelle et Ostéopathie
🎓 Diplômes
- DE Docteur en médecine
Source : Annuaire Santé ANS (FHIR Practitioner.qualification) · Mises à jour quotidiennes.
🏆 DU / DIU rhumato reconnus
Activité de recherche & publications
Source : bases de données publiques (OpenAlex, PubMed).
h-index
1
h articles cités ≥ h fois chacun. Un h de 1 = 1 publications avec 1+ citations.
Citations
291
Publications
9
i10-index
1
Thématiques principales
- Historical and Literary Studies ×3
- Historical Studies and Socio-cultural Analysis ×2
- Historical Art and Culture Studies ×2
- Death, Funerary Practices, and Mourning ×2
- Rheumatoid Arthritis Research and Therapies ×1
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Bibliographie
COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study
2021ArticleThe Lancet Rheumatology
Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients
2020ArticleAnnals of the Rheumatic Diseases
Alexandrie 1914-1918
2014Ouvrage
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
Localisation
Adresses géocodées via la Base Adresse Nationale (api-adresse.data.gouv.fr). Précision indicative.
Lieu de consultation
CABINET DU DR NICOLE GARNIER
BAT E — 4 RUE BERNADET, 31830 Plaisance-du-Touch
☎ 0534521092Libéral© OpenStreetMap
Tarifs & secteur de conventionnement
Prendre rendez-vous & contact
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Top publications · les plus citées
- 1Impact of age at diagnosis, sex, and immunopathological manifestations in 886 patients with pediatric chronic immune thrombocytopenia
American journal of hematology · 2023
Lire l'abstract Crossref ↓
AbstractPediatric chronic immune thrombocytopenia (cITP) is a heterogeneous condition in terms of bleeding severity, second‐line treatment use, association with clinical and/or biological immunopathological manifestations (IMs), and progression to systemic lupus erythematosus (SLE). No risk factors for these outcomes are known. Specifically, whether age at ITP diagnosis, sex, or IMs impact cITP outcomes is unknown. We report the outcomes of patients with pediatric cITP from the French nationwide prospective cohort OBS'CEREVANCE. We used multivariate analyses to investigate the effect of age at ITP diagnosis, sex, and IMs on cITP outcomes. We included 886 patients with a median (min‐max) follow‐up duration of 5.3 (1.0–29.3) years. We identified an age cutoff that dichotomized the risk of the outcomes and defined two risk groups: patients with ITP diagnosed <10 years (children) and ≥ 10 years (adolescents). Adolescents had a two to four‐fold higher risk of grade ≥3 bleeding, second‐line treatment use, clinical and biological IMs, and SLE diagnosis. Moreover, female sex and biological IMs were independently associated with higher risks of biological IMs and SLE diagnosis, second‐line treatment use, and SLE diagnosis, respectively. The combination of these three risk factors defined outcome‐specific risk groups. Finally, we showed that patients clustered in mild and severe phenotypes, more frequent in children and adolescents, respectively. In conclusion, we identified that age at ITP diagnosis, sex, and biological IMs impacted the long‐term outcomes of pediatric cITP. We defined risk groups for each outcome, which will help clinical management and further studies.
- 2Antinuclear antibody-associated autoimmune cytopenia in childhood is a risk factor for systemic lupus erythematosus
Blood · 2024
📚 10 citations🎯 RCR 3.53Top 13% NIH🩺 CliniqueLire l'abstract Crossref ↓
Abstract Autoimmune cytopenia (AIC) in children may be associated with positive antinuclear antibodies (ANA) and may progress to systemic lupus erythematosus (SLE). We evaluated the risk of progression to SLE of childhood-onset ANA-associated AIC. In the French national prospective OBS’CEREVANCE cohort, the long-term outcome of children with ANA-associated AIC (ANA titer ≥1/160) and a subgroup of children who developed SLE were described. ANA were positive in 355 of 1803 (20%) children with AIC. With a median follow-up of 5.8 (range, 0.1-29.6) years, 79 of 355 (22%) patients developed SLE at a median age of 14.5 (1.1-21.4) years; 20% of chronic immune thrombocytopenic purpura, 19% of autoimmune hemolytic anemia, and 45% of Evans syndrome. None of the patients with ANA-negative test developed SLE. Severe manifestations of SLE were observed in 21 patients, and 2 patients died. In multivariate analysis including patients with positive ANA within the first 3 months after AIC diagnosis, age &gt;10 years at AIC diagnosis (relative risk [RR], 3.67; 95% confidence interval [CI], 1.18-11.4; P = .024) and ANA titer &gt;1/160 (RR, 5.28; 95% CI, 1.20-23.17; P = .027) were associated with the occurrence of SLE after AIC diagnosis. ANA-associated AIC is a risk factor for progression to SLE, especially in children with an initial ANA titer &gt;1/160 and an age &gt;10 years at AIC diagnosis. ANA screening should be recommended in children with AIC, and patients with ANA should be monitored long-term for SLE, with special attention to the transition period. This trial was registered at www.ClinicalTrials.gov as #NCT05937828.
- 3Liverpool Epidemic Strain Isolates of Pseudomonas aeruginosa Display High Levels of Antimicrobial Resistance during Both Planktonic and Biofilm Growth
Microbiology spectrum · 2022
📚 9 citations🎯 RCR 1.07🔓 Open AccessLire l'abstract Crossref ↓
Pseudomonas aeruginosa is an opportunistic pathogen with high intrinsic antibiotic resistance. This resistance is typically increased in clinical isolates through adaptations to the host and production of small-colony variants (SCVs) and when P. aeruginosa forms biofilms, which are surface-attached communities that are protected by a self-produced matrix.
Publications scientifiques (8) — classées par pathologie
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Transversal5
▼
Transversal5
▼- Childhood isolated C3d-positive AIHA: favorable prognosis but rare relapse or associated immunodeficiency
Blood advances · 2026 · Journal Article
Blachez M, Aladjidi N, Modot T, Fernandes H, et al.
📚 1 cit. - Neisseria gonorrhoeae antimicrobial susceptibility testing: application of traditional agar dilution to a high-throughput 96-well microtiter assay
Microbiology spectrum · 2025 · Journal Article
Kuipers JE, Seidel L, Garnier NE, Khursigara CM
📚 1 cit. - AAV-vectored expression of monospecific or bispecific monoclonal antibodies protects mice from lethal Pseudomonas aeruginosa pneumonia
Gene therapy · 2024 · Journal Article
Lopes JA, Garnier NE, Pei Y, Yates JGE, et al.
📚 5 cit. - Liverpool Epidemic Strain Isolates of Pseudomonas aeruginosa Display High Levels of Antimicrobial Resistance during Both Planktonic and Biofilm Growth
Microbiology spectrum · 2022 · Journal Article
Goodyear MC, Garnier NE, Levesque RC, Khursigara CM
📚 9 cit.🎯 RCR 1.07 - Label-free quantitative proteomics identifies unique proteomes of clinical isolates of the Liverpool Epidemic Strain of Pseudomonas aeruginosa and laboratory strain PAO1
Proteomics. Clinical applications · 2021 · Journal Article
Goodyear MC, Garnier N, Krieger JR, Geddes-McAlister J, et al.
📚 4 cit.
Pédiatrie2
▼
Pédiatrie2
▼- Pediatric refractory chronic immune thrombocytopenia: Identification, patients' characteristics, and outcome
American journal of hematology · 2024 · Journal Article
Pincez T, Fernandes H, Fahd M, Pasquet M, et al.
📚 5 cit.🎯 RCR 1.33 - Impact of age at diagnosis, sex, and immunopathological manifestations in 886 patients with pediatric chronic immune thrombocytopenia
American journal of hematology · 2023 · Journal Article
Pincez T, Fernandes H, Pasquet M, Abou Chahla W, et al.
📚 14 cit.🎯 RCR 2.50
Lupus1
▼
Lupus1
▼- Antinuclear antibody-associated autoimmune cytopenia in childhood is a risk factor for systemic lupus erythematosus
Blood · 2024 · Clinical Trial
Granel J, Fernandes H, Bader-Meunier B, Guth A, et al.
📚 10 cit.🎯 RCR 3.53🩺 Clinique
Datasets & protocoles partagés
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).
